Albireo is an independent Swedish biotechnology company based in Gothenburg, with broad experience in the GI and liver disease area and a pipeline of programmes for underserved markets.

Albireo is focused on developing novel therapies that address unmet medical needs in the GI area. Specifically, they are concentrating on generating significant clinical data for their lead programme in chronic constipation, and on progressing our pre-clinical assets into the clinic. Their clinical pipeline includes product candidates that are designed to act locally to restore normal bile acid levels and treat diseases and disorders associated with irregularities in bile acid biology.